Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024

The chronic obstructive pulmonary disease (copd) treatment market has grown strongly in recent years. It will grow from $20.08 billion in 2023 to $21.09 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The expansion observed in the historical period can be ascribed to several contributing factors, including the smoking epidemic and widespread tobacco use, advancements in inhalation therapies, increased awareness through awareness programs and early diagnosis initiatives, government-led initiatives for respiratory health, and notable research and development efforts in the field of pulmonology.

The chronic obstructive pulmonary disease (copd) treatment market is expected to see strong growth in the next few years. It will grow to $26.06 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The anticipated growth in the forecast period can be linked to various factors, including the rise of personalized medicine and biomarker research, the emergence of biologic therapies and targeted interventions, growing concerns about air quality and environmental factors, global initiatives focused on smoking cessation, and collaborative efforts for drug development. Noteworthy trends expected in this period encompass the integration of digital health solutions for COPD management, the introduction of biologic therapies tailored for COPD, the increasing prominence of personalized medicine, the utilization of combination therapies and inhalers, a focus on early diagnosis and intervention, and the implementation of pulmonary rehabilitation programs.

The growth projections for the chronic obstructive pulmonary disease (COPD) treatment market are fueled by the increasing prevalence of lung disease, a condition that adversely impacts lung function. Lung diseases, including asthma, COPD, and lung cancer, are widespread, affecting millions globally. COPD treatment plays a crucial role in addressing lung diseases by managing symptoms, slowing disease progression, and preventing lung damage through the use of inhalers and medications. For example, as of September 2022, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) reported that 3.2 million people succumb to COPD annually, impacting approximately 200 million individuals. Additionally, the prevalence of asthma globally in 2022 reached 262 million people, and the LUNGevity Foundation projected that lung cancer would cause 127,000 annual deaths in the US alone by 2023. This increasing prevalence of lung diseases propels the growth of the COPD treatment market.

The trajectory of the chronic obstructive pulmonary disease (COPD) treatment market is further influenced by the rising prevalence of smoking. Smoking, involving the inhalation of smoke, particularly from burning substances such as tobacco, is a significant contributor to respiratory issues and COPD. Treatment for COPD is increasingly sought after by individuals who smoke, aiming to enhance breathing, improve quality of life, reduce exacerbations, enhance exercise tolerance, increase longevity, and improve mental health. As of July 2023, a report from The World Health Organization revealed that tobacco-related deaths exceed 8 million annually, with 1.3 million non-smokers affected by second-hand smoke inhalation. The escalating prevalence of smoking underscores the driving force behind the growth of the COPD treatment market.

A notable trend in the chronic obstructive pulmonary disease (COPD) treatment market is the emphasis on product innovation by major industry players. Companies operating in this market are actively engaged in the development of innovative products to strengthen their market position. For example, in April 2022, GlaxoSmithKline plc (GSK), a leading UK-based pharmaceutical and biotechnology company, introduced Trelegy Ellipta - a groundbreaking single-inhaler triple treatment (SITT) for patients with COPD in India. Trelegy Ellipta, comprising fluticasone furoate, umeclidinium, and vilanterol, serves as a maintenance medication for treating and preventing COPD symptoms in individuals aged 18 and older. The product's mechanism involves mimicking natural corticosteroid hormones, reducing immune system activity, and alleviating airway swelling for improved breathing.

Innovative product development continues to be a strategic focus for major companies in the COPD treatment market, exemplified by offerings such as Vilfuro-G. Launched by Lupin Limited, an India-based pharmaceutical company in November 2023, Vilfuro-G stands as the world's first fixed-dose triple combination medication (FDC) designed to effectively treat COPD. With a fixed, once-daily dosage, Vilfuro-G is expected to significantly enhance the lives of COPD patients, expanding Lupin's respiratory product line and showcasing the company's commitment to delivering cutting-edge treatment options. As the only FDC tailored to combine glycopyrronium bromide, vilanterol, and fluticasone furoate, Vilfuro-G addresses the long-term treatment and management of moderate to severe COPD.

In March 2023, a collaboration between UC Davis Health, a US-based health system, and Propeller Health, a US-based digital health company specializing in respiratory health, further exemplifies the trend of integrating digital health technologies into COPD treatment. This partnership aims to utilize Propeller's remote monitoring program, incorporating sensors, a mobile app, a web interface, and personalized support to deliver individualized treatment for high-risk patients with chronic respiratory illnesses such as asthma and COPD. This collaboration underscores a commitment to leveraging digital health solutions to enhance clinical outcomes and improve care for individuals with chronic conditions.

Major companies operating in the chronic obstructive pulmonary disease (copd) treatment market report are Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Abbott Laboratories, Chiesi Farmaceutici S.p.A, Mylan N.V., Orion Corporation, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Circassia Group PLC, Kyowa Kirin Co. Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Alcon Laboratories Inc., Amgen Inc., Apotex Inc., Aurobindo Pharma Limited, Biocon Limited, Biogen Inc., Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals plc, Lupin Limited, Meda AB, Mundipharma International Limited, Pfizer Inc.

North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2023. Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (copd) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic obstructive pulmonary disease (copd) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key pharmaceutical interventions in chronic obstructive pulmonary disease (COPD) treatment include combination therapy, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokinetics, and other drug classes. Combination therapy involves the administration of multiple therapies to address the complex nature of COPD. This approach entails providing patients with a range of tablets, each containing specific medications. Widely utilized in the treatment of conditions such as chronic bronchitis and emphysema, combination therapy is prevalent in healthcare settings, including hospitals, clinics, and homecare, as part of the COPD treatment regimen.

The chronic obstructive pulmonary disease (COPD) treatment market research report provides chronic obstructive pulmonary disease (COPD) treatment market statistics, including chronic obstructive pulmonary disease (COPD) treatment industry global market size, regional shares, competitors with a chronic obstructive pulmonary disease (COPD) treatment market share, detailed chronic obstructive pulmonary disease (COPD) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chronic obstructive pulmonary disease (COPD) treatment industry. This chronic obstructive pulmonary disease (COPD) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic obstructive pulmonary disease (COPD) treatment market includes revenues earned by entities by providing services such as oxygen therapy, pulmonary rehabilitation, medication services, endobronchial valve therapy and non-invasive ventilation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.